The company's last Venture Round investment, which took place on 03 November 2016, was secured from Enterprise Ireland. OrthoXel plans to advance the Apex Tibial Nailing system through regulatory approval and clinical studies in early 2017, followed by the Apex Femoral Nailing system. This innovative product, backed by rigorous testing and supported by an investment from Enterprise Ireland, positions Orthoxel as a promising player in the biotechnology and healthcare industries.
Orthoxel
Introducing a novel intramedullary nail designed for optimal treatment of tibia and femoral fractures, backed by extensive R&D and rigorous testing.
Founded 2014
11-50 employees
Venture round
Biotechnology, Health Care
General Information
Company Name
Orthoxel
Founded Year
2014
Employees
11-50
Industries
Biotechnology, Health Care
Funding Stage
Venture round
Social
BounceWatch is an independent company data service, not affiliated with Orthoxel. To contact Orthoxel, visit orthoxel.net.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Orthoxel compare?
A PDF of Orthoxel and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Orthoxel soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is Orthoxel on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
About Orthoxel
Business keywords: Orthopedic Trauma, Tibial Nail System, Femoral Nail System, Orthopaedic Surgery, Surgical Implants, Fracture Fixation, Intramedullary Nailing, Clinical Study, Start-up, Orthopedic Research, R&D, Trauma Devices
Funding Rounds & Investors (1)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Venture Round | Undisclosed | 1 |
|
03 Nov 2016 |
Orthoxel Alternatives & Competitors
View All Alternatives
Orthoxel vs
Pioneering the future of orthopedic trauma treatment with a specialized intramedullary nailing syste...
Debt Financing
1 employees
Biotechnology, Health Care
Orthoxel vs
The innovative technology platform offers swift, minimally invasive surgical solutions for active in...
Venture round
1 employees
Biotechnology, Health Care
Orthoxel vs
BONESUPPORT AB
Sweden
Restoring health to improve the quality of life for patients with bone disorders.
Post-IPO Equity
163 employees
Biotechnology, Health Care
FAQ About Orthoxel
Introducing a novel intramedullary nail designed for optimal treatment of tibia and femoral fractures, backed by extensive R&D and rigorous testing.
Orthoxel was founded in 2014.
Orthoxel operates in Biotechnology and Health Care. Its work centres on Orthopedic Trauma, Tibial Nail System, Femoral Nail System and Orthopaedic Surgery.
Orthoxel has approximately 11-50 employees.
Orthoxel has completed 1 funding round. The latest funding stage is Venture round.
Top alternatives and competitors to Orthoxel include DGIMED ORTHO, Sonoma Orthopedics, BONESUPPORT AB, SpineSmith, Innovasis, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Orthoxel and DGIMED ORTHO are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for Orthoxel, https://bouncewatch.com/company/orthoxel, updated 28 October 2024. When citing, please name BounceWatch and link this page.
